A new oral anti-viral drug has stirred hope that Covid-19 could be treated by a pill.
The drug known as molnupiravir was developed for the treatment of influenza and has now been found to reduce chances of hospitalistion or death by half for patients at risk of severe disease, according to interim clinical trial results announced yesterday.
If authorised, molnupiravir would be the first oral antiviral medication for Covid-19. So far, only antibody cocktails, which have to be given intravenously, are approved for treating non-hospitalised Covid-19 patients. The drug, molnupiravir, is administered orally and is designed to inhibit the replication of the coronavirus inside the body by introducing errors into the genetic code of the SARS-CoV-2 virus.
According to the American multinational pharmaceutical company Merck & Co Inc, which developed the drug, Phase 3 trial dubbed MOVe-OUT has been stopped early due to the positive results seen in mild or moderate Covid-19.
Merck, in partnership with another US based company, Ridgeback Biotherapeutics, announced that it plans to apply for emergency use authorisation (EUA) for the pill ‘as soon as possible’, and to submit applications to regulatory agencies globally.
“With these compelling results, we are optimistic that molnupiravir can become an important medicine as part of the global effort to fight the pandemic and will add to Merck’s unique legacy of bringing forward breakthroughs in infectious diseases when they are needed most,” said Robert M. Davis, the chief executive officer, and president.
The 775 study participants had laboratory-confirmed symptoms of Covid-19 and were randomly given molnupiravir or a placebo within five days of symptoms.
“Antiviral treatments that can be taken at home to keep people with Covid-19 out of the hospital are critically needed,” Wendy Holman, Ridgeback’s CEO, said in a statement.
A placebo is a substance or treatment which is designed to have no therapeutic value. It could be a pill, a shot, or some other type of “fake” treatment. What all placebos have in common is that they do not contain an active substance meant to affect health. Researchers use placebos during studies to help them understand what effect a new drug or some other treatment might have on a particular condition, according to WebMD.
In the trial, which enrolled patients around the world, molnupiravir was taken every 12 hours for five days. According to the study, molnupiravir was also found to be effective across Covid-19 variants like Gamma, Delta, and the newly discovered Mu.
Merck said it expects to produce 10 million courses of the treatment by the end of 2021, with more doses coming next year as it has a US government contract to supply 1.7 million courses of molnupiravir at a price of $700 (about Sh77,350) per course.
Other pharmaceutical companies like Pfizer and Swiss’s Roche are also racing to develop an easy-to-administer antiviral pill for the disease, which has infected about 219 million people, killing 4.5 million of them.
In Kenya, 249,725 have tested positive for the disease and 5,128 succumbed.
The news comes days after a study (on 500 patients) published in the New England Journal of Medicine on August 18 showed that the use of convalescent plasma treatment for high-risk patients early in the disease was not as effective as earlier thought.
Covid-19 convalescent plasma
Covid-19 convalescent plasma has been used at Kenyatta University Teaching Referral and Research Hospital (KUTRRH) as an experimental therapy for a number of patients.
Treating Covid-19 patients with convalescent plasma infusions was thought to help fight the virus after studies suggested that the treatment might lower the risk of death among hospitalised patients if administered early in the disease — before mechanical assistance was needed to help them breathe.
In the NEJM study, the research team found there was no significant difference in disease progression between the plasma group and those given a placebo. The trial was stopped in February due to the lack of treatment efficacy.
“The results show that convalescent plasma does not appear to benefit this particular group,” says study co-author Dr Nahed El Kassar of NHLBI. “But the findings answer an important clinical question and may help bring researchers a step closer to finding more effective treatments against this devastating disease.”
Credit: Source link